Phase I results for CVT-510 presented at ACR meeting; CV designs new partial agonist derivative March 21, 2000
TxA2 antagonist from Bayer may have potential in atherosclerosis according to ACC presentation March 20, 2000
Cariporide: no improvement in myocardial stunning/infarct size in GUARDIAN trial subgroup March 20, 2000
RSS